Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Abstract

Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).

Keywords

Affiliated Institutions

• Western University CA
• Columbia University Irving Medical Center US
• Université Toulouse III - Paul Sabatier FR
• University of Milan IT
• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico IT
• The University of Melbourne AU
• King's College Hospital GB
• University Hospital Heidelberg DE
• Inserm FR
• Karolinska University Hospital SE
• Indiana University School of Medicine
• Fundació ACE ES
• Indiana University US
• Victoria Hospital GB
• Hannoversche Kinderheilanstalt DE
• Centre Hospitalier Universitaire de Toulouse FR
• Diakovere DE
• Heidelberg University DE
• Eli Lilly (Singapore) SG
• Karolinska Institutet SE

Related Publications